GSK Acquires Chimagen Multiple Myeloma TCE
Analysis based on 8 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026
The deal is a modest bolt-on acquisition for GSK that strengthens its oncology pipeline and multiple myeloma portfolio without materially altering near-term earnings, and GSK shares rose around 0.92 percent in overnight NYSE activity. Sentiment for the broader biotech sector is mildly positive as it signals continued large-pharma appetite for clinical-stage multi-specific antibody assets, though the transaction is too small to move the wider market.
GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement has a total potential value of up to $750 million, comprising an upfront payment for full global rights to the TCE programme plus success-based development and commercial milestone payments, and remains subject to customary closing conditions. The candidate is designed to bind to T cells while simultaneously targeting two strategically selected and validated tumour-associated antigens, aiming to improve on the efficacy and tolerability limitations of existing TCE therapies. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027. The deal complements GSK's existing multiple myeloma franchise, which includes Blenrep (belantamab mafodotin), and builds on a prior agreement with Chimagen to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders. GSK cited forecasts that the US TCE market for multiple myeloma could exceed $10 billion by 2032. Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year, and remains generally incurable. Noor Hisham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, said the deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer. Zhenhao Zou, CEO of Chimagen Biosciences, said the agreement marks another major milestone for the company's platforms.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard